Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C virus

Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C virus

US Patent 11660332 · Granted May 30, 2023

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Peptide vaccine based on a new universal influenza a hemagglutinin head domain e2025
Methods of lipid nanoparticle manufacture and compositions derived therefrom2025
Human monoclonal antibodies to enterovirus D682025
Nucleoside modified mRNA and uses thereof2025
Conserved region T cell vaccines for coronavirus and methods of use2025
Human monoclonal antibodies to a new universal influenza A hemagglutinin head do2025
Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C viru2025
Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C viru2025
Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C viru2025
Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C viru2025
Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C viru2025
Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C viru2025